Altimmune's CMO will present Phase 2 trial data on pemvidutide for obesity at an upcoming conference in Washington, D.C.Quiver AI SummaryAltimmune, Inc. has announced that its Chief Medical Officer, Dr....
Altimmune ALT is developing its lead candidate, pemvidutide, a novel, investigational and peptide-based GLP-1/glucagon dual receptor agonist for treating obesity and metabolic dysfunction-associated steatohepatitis...
Pemvidutide showed significant reductions in inflammatory lipids, supporting its potential benefits for metabolic dysfunction-related conditions.Quiver AI SummaryAltimmune, Inc. announced favorable results...
In a remarkable turn of events, Altimmune (NASDAQ: ALT) witnessed a staggering 27% surge in its stock price this morning, fueled by promising clinical data from its Phase 2 trials and heightened investor...
Altimmune is betting big on its investigational metabolic diseases candidate pemvidutide.
The new hire’s background includes CFO roles at several biotech firms acquired in high-profile deals, such as Sirna Therapeutics (acquired by Merck) and ILEX Oncology (acquired by Genzyme).